Showing results (2341-2350 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|December 28, 2005
In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drugEsther F A Brandon, Rolf W Sparidans, Kees-Jan Guijt, et al.
Investigational New Drugs|December 29, 2005
Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinomaJacqueline Vuky, Christina Isacson, Mehran Fotoohi, et al.
Investigational New Drugs|October 17, 2009
Characterization of the cell growth inhibitory effects of a novel DNA-intercalating bipyridyl-thiourea-Pt(II) complex in cisplatin-sensitive and -resistant human ovarian cancer cellsGaetano Marverti, Alessio Ligabue, Monica Montanari, et al.
Investigational New Drugs|January 1, 1985
Effect of inhibition of gamma-glutamyltranspeptidase by AT-125 (acivicin) on glutathione and cysteine levels in rat brain and plasmaK E Hill, D D Von Hoff, R F Burk
Investigational New Drugs|June 10, 2017
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trialsJean-Marie Michot, Lina Benajiba, Laura Faivre, et al.
Investigational New Drugs|April 27, 2018
Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptidesTammy Price-Troska, Zhi-Zhang Yang, David Diller, et al.
Investigational New Drugs|May 22, 2018
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumorsA Craig Lockhart, Todd M Bauer, Charu Aggarwal, et al.
Investigational New Drugs|December 1, 1988
Trimetrexate in advanced carcinoma of the esophagusA S Alberts, G Falkson, M Badata, et al.
Investigational New Drugs|May 17, 2018
A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancersAflah Roohullah, Adam Cooper, Anna J Lomax, et al.
Investigational New Drugs|April 4, 2018
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumorsCarol Aghajanian, Katherine M Bell-McGuinn, Howard A Burris, et al.
Pageof 372